BVS · Bioventus Inc.

Bioventus delivered a strong first quarter with $132.1 million in revenue, up 7% year-over-year, driven by broad-based growth across its three core businesses—Pain Treatments ($63.4M, +7.7%), Surgical Solutions ($48.0M, +6.2%), and Restorative Therapies ($20.6M, +4.6%). The U.S. segment contributed $116.4 million (+5.4%), buoyed by favorable rebate adjustments and demand for Surgical Solutions and EXOGEN; international revenue rose 17.1% to $15.6 million, led by volume gains in Surgical Solutions and Pain Treatments. Financially, the Company swung from a $2.6 million net loss to $3.1 million net income, lifting GAAP diluted EPS from ($0.04) to $0.04. Non-GAAP EPS surged 88% to $0.15, reflecting improved operating profitability and reduced interest expense. Adjusted EBITDA grew 24% to $23.9 million, supported by higher gross profit and favorable FX. Management attributed performance to disciplined execution, commercial effectiveness, and momentum in core offerings. Notably, Bioventus raised full-year 2026 Adjusted EPS guidance to $0.75–$0.79 and Cash from Operations guidance to $84–$89 million—both increases of $0.02 and $2 million, respectively—citing stronger-than-expected cash generation and $22.0 million in discretionary debt prepayment on March 27, 2026. Revenue guidance remains unchanged at $600–$610 million, implying 6–7% annual growth. CEO Rob Claypoole emphasized focus on above-market growth, peer-leading gross margins, and reinvestment into growth drivers—all aimed at delivering sustainable long-term shareholder value.